Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Sina Grebhardt"'
Autor:
Uwe M. Martens, Jan Schröder, Fee Bengsch, Ludger Sellmann, Sabine Busies, Stefanie Frank-Gleich, Matthias Zaiss, Thomas Decker, Andreas Schneeweiss, Martin Schuler, Sina Grebhardt, Stefan Zacharias, Norbert Marschner, Benjamin Kasenda, Karin Potthoff, Corinne Vannier
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-7 (2023)
Abstract Background Precision oncology, defined as treatment of patients with targeted therapies matched to specific molecular alterations, has entered routine clinical practice. Particularly in patients with advanced cancer or hematologic malignanci
Externí odkaz:
https://doaj.org/article/2ff76df191ae40ff907e5d9eb595b081
Autor:
Christian Geßner, Thomas Fietz, Christoph Losem, Andreas Lück, Holger Schulz, Beate Niemeier, Matthias Groschek, Henning Eschenburg, Rudolf Weide, Albrecht Kretzschmar, Nikolaj Frost, Joachim Hipp, Johanna Harde, Christiane D. Matillon, Sina Grebhardt, Karin Potthoff
Publikováno v:
Current Medical Research and Opinion. 38:2191-2199
Real-world evidence on the application of the granulocyte colony-stimulating factor lipegfilgrastim for the reduction of chemotherapy-induced neutropenia and febrile neutropenia (FN) is limited. The NADIR study aimed to evaluate effectiveness and saf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cde4f1b9554956f7cf3bc449ab3581ab
https://doi.org/10.1080/03007995.2022.2113693
https://doi.org/10.1080/03007995.2022.2113693
Autor:
Matthias Groschek, Corinne Vannier, Sina Grebhardt, Hans Ulrich Siebenbach, Ulrike Söling, Tobias Dechow, Timo Behlendorf, Ali Aldaoud, Karin Potthoff, Wolfgang Knauf, Henning Eschenburg, Richard A. Hansen
Publikováno v:
European Journal of Haematology. 108:133-144
Background Prognosis of patients with multiple myeloma (MM) who have relapsed on or become refractory to immunomodulators and bortezomib is poor and treatment options are limited. While pomalidomide plus low-dose dexamethasone (POM/DEX) has demonstra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c4f14a8c0d36734de8ff27b96816750
https://doi.org/10.1111/ejh.13719
https://doi.org/10.1111/ejh.13719
Autor:
Christiane D Matillon, Michael Metz, Ulrich Hutzschenreuter, Mark-Oliver Zahn, Steffen Liebers, Andreas Lorenz, Dieter Semsek, Gerlinde Egerer, Michael Berghorn, Carsten Hielscher, Stefan Zacharias, Johanna Harde, Gunther Rogmans, Sina Grebhardt, Karin Potthoff, Dagmar Guth, Thomas Fietz
Publikováno v:
Supportive Care in Cancer
Purpose The on-body injector (OBI) automatically delivers pegfilgrastim the day after chemotherapy (CTx), thus eliminating the need of return visits to the medical office for guideline-compliant pegfilgrastim administration. The CONVENIENCE study aim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::514d4e3f09dea24ed5dc11624667452c
https://doi.org/10.1007/s00520-021-06230-9
https://doi.org/10.1007/s00520-021-06230-9
Autor:
Sina Grebhardt, Arnd Nusch, Richard A. Hansen, Ulrike Söling, Johanna Harde, Karin Potthoff, Norbert Marschner, Christoph Salat
Publikováno v:
Clinical Breast Cancer. 18:e1323-e1337
One of the most effective chemotherapies for metastatic breast cancer (MBC) is nab-paclitaxel (nab-P), which is approved for treatment of MBC after failure of first-line therapy and when anthracyclines are not indicated. Randomized clinical trials ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b69dcad4fcd3290065284f66e18f1ab7
https://doi.org/10.1016/j.clbc.2018.07.010
https://doi.org/10.1016/j.clbc.2018.07.010
Autor:
Andreas Lück, Sina Grebhardt, Thomas Fietz, Karin Potthoff, Thomas Wolff, Christoph Losem, Udo Müller, Christian M. Kurbacher, Holger Schulz, Matthias Zaiss, Johanna Harde
Publikováno v:
Current medical research and opinion. 35(7)
Objectives: The non-interventional study (NIS) NADIR (DRKS00005711) evaluated the effectiveness and safety of prophylaxis with lipegfilgrastim, a glycopegylated granulocyte-colony stimulating facto...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9517d06fba4c6f39c8513b070afabbbd
https://pubmed.ncbi.nlm.nih.gov/30557099
https://pubmed.ncbi.nlm.nih.gov/30557099
Autor:
Thomas Wolff, Holger Schulz, Sina Grebhardt, Dietmar Reichert, Karin Potthoff, Reiner Sandner, Thomas Fietz, Udo Mueller, Johanna Harde, Hans-Jürgen Hurtz, Christoph Losem
Publikováno v:
European journal of haematology. 102(2)
Objective The prospective non-interventional study (NIS) NADIR was designed to evaluate both effectiveness and safety of prophylactic use of lipegfilgrastim (Lonquex® ), a glycopegylated granulocyte colony-stimulating factor, in cancer patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef7dfa0ad8e80397b8f957a76834a2ab
https://pubmed.ncbi.nlm.nih.gov/30347466
https://pubmed.ncbi.nlm.nih.gov/30347466
Publikováno v:
Journal of Cellular Physiology. 229:661-671
The proinflammatory S100A8/A9 proteins, which are expressed in myeloid cells under physiological conditions, are strongly expressed in human prostate cancer epithelial cells. Their role in the tumor cells and in tumor progression is largely unclear.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a3e102fd35c77441f01333a48483bdef
https://doi.org/10.1002/jcp.24489
https://doi.org/10.1002/jcp.24489
Publikováno v:
Cancers
Cancers, Vol 3, Iss 3, Pp 2990-3001 (2011)
Cancers; Volume 3; Issue 3; Pages: 2990-3001
Cancers, Vol 3, Iss 3, Pp 2990-3001 (2011)
Cancers; Volume 3; Issue 3; Pages: 2990-3001
Estrogen receptor-alpha (ERα) is a key factor in the development of breast cancer in humans. The expression and activity of ERα is regulated by a multitude of intracellular and extracellular signals. Here we show a cross-talk between β-catenin and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca69e4073818ba918f504d7d1e4f4c91
https://doi.org/10.3390/cancers3032990
https://doi.org/10.3390/cancers3032990
Publikováno v:
Biochemical Pharmacology. 78:1366-1373
FOLFOX is a cytostatic drug combination for adjuvant treatment of colorectal cancer (CRC) consisting of 5-fluorouracil (5-FU), leucovorin, and oxaliplatin. The mechanism of synergistic interaction of these drugs is poorly understood and little is kno
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4e065fa20d9401118f3f250d86b6837
https://doi.org/10.1016/j.bcp.2009.07.006
https://doi.org/10.1016/j.bcp.2009.07.006